U-2 OS Gal4-p300 Cell Line is a U2-OS cell expressing Gal4-p300. Available from the non-profit biorepository CancerTools.org
| Inventor | Institute |
|---|---|
| Yili Yin | University of Dundee |
| SKU: | 151579 |
|---|---|
| Product description: | U2-OS cells expressing Gal4-p300. p300 is a transcriptional coactivator that functions as integrator of numerous signaling pathways and are utilized by many DNA binding proteins to facilitate transcriptional activation. p300 shares numerous conserved domains with CREB binding protein (CBP), which is also a transcriptional coactivator. These shared domains include a histone acetyl transferase (HAT) domain, a bromo domain, and three cysteine- and histidine-rich domains. CBP also interacts with the RNA polymerase II holoenzyme and p300/CBP both contain transcriptional activation domains that function independently of HAT activity. |
| Production details: | U2-OS cells were co-transfected with both the Gal4p300CRD1 expression vector (zeocin selection marker, backbone: pcDNA4/TO) and the Gal4-EIB-luciferase reporter vector (neomycin selection marker, backbone: pCG4 without the CMV promoter) using Fugene 6 transfection reagent.24 hours after transfection, stable transfectants were selected using G418 3.0 mg /ml and Zeocin 3.0 mg/ml until massive cell death, and then grown under G418 0.5 mg /ml and Zeocin 0.5 mg/ml for further selection. Establishe… |
| Parental cell line: | U-2 OS |
| Disease: | Cancer |
| Cat. #: | 151579 |
|---|---|
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Research Fields: | Genetics |
| Organism: | Human |
| Model: | Transgenic |
| Cancer Types In Detail: | Osteosarcoma |
| Format: | Frozen |
|---|---|
| Storage conditions: | Vapor phase of liquid nitrogen. Storage at -70° C will result in loss of viability. |
| Shipping conditions: | Dry ice |
| Growth medium: | DMEM plus 10% Foetal Bovine Serum and 1% Penicillin-Streptomycin |
| Recommended controls: | U-2 OS parental line |
| References: |
Girdwood et al. 2003. Mol Cell. 11(4):1043-54. PMID: 12718889. P300 transcriptional repression is mediated by SUMO modification. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.